6 analysts rate Aerovate Therapeutics (AVTE) as "Hold" with a $2.25 target price.
6 analysts covering Aerovate Therapeutics (AVTE) have assigned a consensus recommendation of "Hold", with an average 12-month target price of $2.25. Evercore ISI lowered its rating from "outperform" to "inline" and cut the price target from $27 to $2, while TD Cowen downgraded from "buy" to "hold". Jefferies Financial Group reaffirmed a "hold" rating, lowering the price objective from $65 to $2.
July 20, 2024
3 Articles